The US National Institutes of Health has made a deal with Pfizer, AstraZeneca, and Eli Lilly to share "abandoned experimental drugs" with academic researchers, reports ScienceInsider's Jocelyn Kaiser. The hope, Kaiser says, is that researchers will be able to find new uses for the drugs. The companies will grant access to two dozen compounds that have passed safety studies, but were deemed ineffective for a specific purpose.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.